{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T13:44:07Z","timestamp":1786974247254,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002975","name":"Sumitomo Pharma Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002975","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jad.2025.05.008","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T11:50:47Z","timestamp":1746445847000},"page":"119348","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Lurasidone for bipolar I depression with comorbid anxiety symptoms: Post-hoc-analysis of randomized, placebo-controlled studies"],"prefix":"10.1016","volume":"385","author":[{"given":"Takeshi","family":"Inoue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiya","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2025.05.008_bb0005","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00228-008-0468-8","article-title":"Who volunteers for phase I clinical trials? Influences of anxiety, social anxiety and depressive symptoms on self-selection and the reporting of adverse events","volume":"64","author":"Almeida","year":"2008","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jad.2025.05.008_bb0010","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2022"},{"issue":"3","key":"10.1016\/j.jad.2025.05.008_bb0015","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2174\/157488609789006985","article-title":"Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications","volume":"4","author":"Citrome","year":"2009","journal-title":"Curr Drug Saf. Sep"},{"key":"10.1016\/j.jad.2025.05.008_bb0020","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1192\/bjp.bp.110.081992","article-title":"Effects of anxiety on the long-term course of depressive disorders","volume":"200","author":"Coryell","year":"2012","journal-title":"Br. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.jad.2025.05.008_bb0025","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1177\/070674370404900503","article-title":"Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: clinical implications","volume":"49","author":"de Haan","year":"2004","journal-title":"Can. J. Psychiatr."},{"issue":"8","key":"10.1016\/j.jad.2025.05.008_bb0035","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.seizure.2012.06.003","article-title":"Severity of anxiety and depression are related to a higher perception of adverse effects of antiepileptic drugs","volume":"21","author":"G\u00f3mez-Arias","year":"2012","journal-title":"Seizure"},{"issue":"1","key":"10.1016\/j.jad.2025.05.008_bb0040","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br. J. Med. Psychol."},{"issue":"3","key":"10.1016\/j.jad.2025.05.008_bb0045","doi-asserted-by":"crossref","first-page":"331","DOI":"10.4088\/JCP.v64n0316","article-title":"Anxiety disorders in 318 bipolar patients: prevalence and impact on illness severity and response to mood stabilizer","volume":"64","author":"Henry","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2025.05.008_bb0050","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.pnpbp.2012.08.005","article-title":"Binding of lurasidone, a novel antipsychotic, to rat 5-HT7 receptor: analysis by [3H]SB-269970 autoradiography","volume":"40","author":"Horisawa","year":"2013","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2025.05.008_bb0055","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.2147\/NDT.S246294","article-title":"Prevalence of comorbid anxiety disorders and their associated factors in patients with bipolar disorder or major depressive disorder","volume":"16","author":"Inoue","year":"2020","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"1","key":"10.1016\/j.jad.2025.05.008_bb0060","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","article-title":"Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity","volume":"334","author":"Ishibashi","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jad.2025.05.008_bb0065","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jad.2020.12.005","article-title":"Lurasidone in the long-term treatment of bipolar I depression: a 28-week open label extension study","volume":"281","author":"Ishigooka","year":"2021","journal-title":"J. Affect. Disord."},{"issue":"12","key":"10.1016\/j.jad.2025.05.008_bb0070","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/pcn.13137","article-title":"Double-blind, placebo-controlled study of lurasidone monotherapy for the treatment of bipolar I depression","volume":"74","author":"Kato","year":"2020","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.jad.2025.05.008_bb0075","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jad.2021.07.104","article-title":"Impact of bipolar disorder on health-related quality of life and work productivity: estimates from the national health and wellness survey in Japan","volume":"295","author":"Kato","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.05.008_bb0080","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jad.2023.05.065","article-title":"The efficacy and safety of lurasidone in bipolar I depression with and without rapid cycling: a pooled post-hoc analysis of two randomized, placebo-controlled trials","volume":"337","author":"Kato","year":"2023","journal-title":"J. Affect. Disord."},{"issue":"5","key":"10.1016\/j.jad.2025.05.008_bb0085","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/da.22479","article-title":"Lurasidone in the long-term treatment of patients with bipolar disorder: a 24-week open-label extension study","volume":"33","author":"Ketter","year":"2016","journal-title":"Depress. Anxiety"},{"issue":"4","key":"10.1016\/j.jad.2025.05.008_bb0090","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1176\/appi.ajp.2019.19010034","article-title":"Dose-response meta-analysis of antipsychotic drugs for acute schizophrenia","volume":"177","author":"Leucht","year":"2020","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2025.05.008_bb0095","doi-asserted-by":"crossref","DOI":"10.1136\/bmjment-2024-301165","article-title":"Efficacy and acceptability of lurasidone for bipolar depression: a systematic review and dose-response meta-analysis","volume":"27","author":"Lin","year":"2024","journal-title":"BMJ Ment Health."},{"issue":"2","key":"10.1016\/j.jad.2025.05.008_bb0100","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1176\/appi.ajp.2013.13070984","article-title":"Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study","volume":"171","author":"Loebel","year":"2014","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2025.05.008_bb0105","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1176\/appi.ajp.2013.13070985","article-title":"Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo- controlled study","volume":"171","author":"Loebel","year":"2014","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.jad.2025.05.008_bb0110","first-page":"215","article-title":"Quetiapine monotherapy as treatment for anxiety symptoms in patients with bipolar depression: a pooled analysis of results from 2 double-blind, randomized, placebo-controlled studies","volume":"11","author":"Lydiard","year":"2009","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.jad.2025.05.008_bb0115","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archgenpsychiatry.2011.12","article-title":"Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative","volume":"68","author":"Merikangas","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2025.05.008_bb0120","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2025.05.008_bb0125","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1017\/S1092852914000285","article-title":"Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies","volume":"20","author":"Nasrallah","year":"2015","journal-title":"CNS Spectr."},{"issue":"1","key":"10.1016\/j.jad.2025.05.008_bb0130","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2025.05.008_bb0135","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/14740338.2017.1379989","article-title":"Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders","volume":"17","author":"Pompili","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"issue":"1","key":"10.1016\/j.jad.2025.05.008_bb0140","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/104012371202400103","article-title":"The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders","volume":"24","author":"Schaffer","year":"2012","journal-title":"Ann. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.jad.2025.05.008_bb0145","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1176\/appi.ajp.157.3.457","article-title":"Low dopamine D2 receptor binding potential in social phobia","volume":"157","author":"Schneier","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2025.05.008_bb0150","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jad.2020.09.119","article-title":"Effects of psychological and pharmacological interventions on anxiety symptoms in patients with bipolar disorder in full or partial remission: a systematic review","volume":"279","author":"Seeberg","year":"2021","journal-title":"J. Affect. Disord."},{"issue":"12","key":"10.1016\/j.jad.2025.05.008_bb0155","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1176\/appi.ajp.161.12.2222","article-title":"Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)","volume":"161","author":"Simon","year":"2004","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.jad.2025.05.008_bb0160","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0165-1781(97)00123-6","article-title":"Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP","volume":"73","author":"Spearing","year":"1997","journal-title":"Psychiatry Res."},{"issue":"4","key":"10.1016\/j.jad.2025.05.008_bb0165","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1176\/appi.ajp.2015.15060770","article-title":"Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double-blind, placebo-controlled study","volume":"173","author":"Suppes","year":"2016","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.jad.2025.05.008_bb0170","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40345-017-0103-7","article-title":"Anxiety, irritability, and agitation as indicators of bipolar mania with depressive symptoms: a post hoc analysis of two clinical trials","volume":"5","author":"Suppes","year":"2017","journal-title":"Int J Bipolar Disord"},{"issue":"1\u20133","key":"10.1016\/j.jad.2025.05.008_bb0175","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jad.2007.03.014","article-title":"Effect of comorbid anxiety on treatment response in bipolar depression","volume":"104","author":"Tohen","year":"2007","journal-title":"J. Affect. Disord."},{"issue":"2","key":"10.1016\/j.jad.2025.05.008_bb0180","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1017\/S1092852917000074","article-title":"Lurasidone for major depressive disorder with mixed features and anxiety: a post-hoc analysis of a randomized, placebo-controlled study","volume":"22","author":"Tsai","year":"2017","journal-title":"CNS Spectr."},{"key":"10.1016\/j.jad.2025.05.008_bb0185","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3389\/fpsyt.2018.00229","article-title":"Prevalence and associated features of anxiety disorder comorbidity in bipolar disorder: a meta-analysis and meta-regression study","volume":"9","author":"Yapici Eser","year":"2018","journal-title":"Front Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2025.05.008_bb0190","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2025.05.008_bb0195","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"Br. J. Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725007621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725007621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:42:59Z","timestamp":1762249379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032725007621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":38,"alternative-id":["S0165032725007621"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2025.05.008","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lurasidone for bipolar I depression with comorbid anxiety symptoms: Post-hoc-analysis of randomized, placebo-controlled studies","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2025.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"119348"}}